Dianthus director Moulder resigns; Read appointed as Class III director

Dianthus Therapeutics, Inc. /DE/

Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.
Board appointed Simon Read, Ph.D. as Class III director and to S&T and N&CG Committees.
Dr. Read receives initial option for 25,000 shares vesting over 3 years; cash compensation of $40k/yr plus $5k per committee.
Annual meeting elected Garcia and Soteropoulos as Class I directors; advisory vote approved exec compensation; Deloitte ratified as auditor.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simon Read

Class III director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2025-05-22
Filed: May 22, 2025, 7:59 PM ET

On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.

Departed

Leon O. Moulder, Jr.

Director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2025-05-22
Successor: Simon Read
Filed: May 22, 2025, 7:59 PM ET

On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Read was appointed as Class III director at Dianthus Therapeutics, Inc. /DE/.

Action: appointed
Role: Class III director

Exact text from the filing

On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Leon O. Moulder, Jr. resigned as Director at Dianthus Therapeutics, Inc. /DE/.

Action: resigned
Role: Director

Exact text from the filing

On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.

View on SEC.gov

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-25-076304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.